Verdad Advisers’s Contineum Therapeutics CTNM Stock Holding History

Verdad Advisers’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Sell	81,014 -5,018	-6%	-$65.8K	1.27%	15
2026 Q1	$1.12M	Buy	+86,032	New	+$1.15M	1.26%	17

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Verdad Advisers's CTNM Position: Q2 2026 in Review

Verdad Advisers reduced its Contineum Therapeutics (CTNM) stake by 5.8% in Q2 2026, selling an estimated $65.8K and leaving 81,014 shares worth $1.33M. The position accounts for 1.27% of the portfolio, ranked #15.

Verdad Advisers first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Verdad Advisers held 81,014 shares of Contineum Therapeutics worth $1.33M as of Q2 2026.
Verdad Advisers sold 5,018 Contineum Therapeutics shares in Q2 2026, an estimated $65.8K.
Contineum Therapeutics made up 1.27% of Verdad Advisers's portfolio in Q2 2026, its #15 holding.
Verdad Advisers first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.